MAPK3 and head and neck squamous cell carcinoma: It has been documented that HNSCC patients with high intratumor expressions of p-MAPK1/3 (p-ERK1/2) have poor survival20, and inhibition of p-ERK1/2 by MAPK pathway inhibitors often inhibited HNSCC cell growth in vitro21–23.